查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401900

到 2030 年治療肌肉骨骼疾病藥物的全球市場預測：按藥物類型、疾病類型、治療類型、給藥途徑、配銷通路、最終用戶和地區進行分析

Musculoskeletal Disorders Drugs Market Forecasts to 2030 - Global Analysis By Drug Type, By Disorder Type, Treatment Type, Route of Administration, Distribution Channel, End User, By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球肌肉骨骼疾病藥物市場規模為 886 億美元，預計在預測期內複合年成長率為 6.2%，到 2030 年將達到 1,351 億美元。

肌肉骨骼疾病藥物是一種旨在治療影響肌肉、骨骼、關節、韌帶和肌腱疾病的藥物。這些疾病包括多種病症，例如關節炎、骨質疏鬆症和肌肉骨骼疼痛。這些疾病包括關節炎、骨質疏鬆症、肌肉骨骼疼痛等多種疾病，治療藥物旨在緩解症狀、控制發炎和抑制疾病進展，有助於提高人們的運動能力和肌肉骨骼系統的整體健康。

據世界衛生組織稱，全球有 17.1 億人患有肌肉骨骼疾病，如類風濕性關節炎、骨關節炎、腰痛、頸部不適、骨折和其他傷害。

肌肉骨骼疾病盛行率上升

肌肉骨骼疾病盛行率的上升是肌肉骨骼疾病治療市場的主要促進因素。人口高齡化、久坐的生活方式和慢性疾病增加等因素導致關節炎、骨質疏鬆症和肌肉骨骼疼痛等肌肉骨骼問題的發生率增加。盛行率的增加使得對有效藥物干預措施的需求激增。因此，製藥公司正在投資研發，從而發現和生產創新藥物並推動市場成長。

副作用和開發成本高

與某些藥物相關的副作用的發生可能會阻礙患者的依從性和接受度。此外，廣泛的研發和臨床試驗過程也會導致更高的開發成本。這些成本的財務負擔阻礙了製藥公司迅速將新的、潛在突破性的肌肉骨骼治療推向市場，限制了患者的治療選擇，並限制了整體市場的成長和有效的治療。藥物的獲取可能會受到影響。

肌萎縮側索硬化症治療藥物的需求迅速增加

對肌萎縮性脊髓側索硬化症藥物的需求不斷成長，為肌肉骨骼疾病藥物市場帶來了巨大的機會。隨著意識的提高，越來越需要有效的治療方法來解決這種使人衰弱的神經退化性疾病。投資開發肌萎縮側索硬化症治療方法的製藥公司可以開拓這個新興市場並滿足患者未滿足的醫療需求。此外，這也將有助於整體市場的成長。

醫療專業人員短缺

肌肉骨骼疾病通常需要風濕病專家、整形外科專家和物理治療師等醫療專業人員的專門護理、診斷和治療。專家的短缺導致患者照護延遲或不足，並妨礙對肌肉骨骼疾病的適當識別和管理。這種短缺可能會導致患者等待時間增加、獲得專家意見的機會有限、實施綜合治療計劃面臨挑戰等，從而影響整體市場成長。

COVID-19 的影響：

COVID-19大流行正在以各種方式影響肌肉骨骼疾病藥物市場。封鎖、衛生服務中斷和經濟不確定性正在影響患者獲得治療的機會。擇期手術和常規預約的延誤正在影響藥物消耗模式。然而，人們對肌肉骨骼健康意識的提高和創新遠端醫療解決方案的開發部分緩解了這段時期的這些挑戰。

幼年特發性關節炎預計在預測期內將是最大的

由於幼年特發性關節炎病例數量不斷增加，預計幼年特發性關節炎細分市場將在預測期內主導肌肉骨骼疾病治療市場。對幼年特發性關節炎的認知不斷提高、早期診斷和不斷發展的治療方案正在促進該領域的發展。藥品的進步，加上對兒童醫學的關注，正在推動研究和開發活動。此外，針對罕見疾病的監管支持和舉措正在進一步擴大該行業的市場佔有率。

預計醫院業在預測期內複合年成長率最高。

醫院領域的肌肉骨骼疾病藥物市場可能會顯著成長。醫院是診斷、治療和管理肌肉骨骼疾病的重要醫療中心。這些疾病的日益流行，加上人口高齡化的加劇，正在推動對專業醫療保健的需求。此外，隨著醫療基礎設施的不斷擴大，醫院領域有望顯著成長。

佔有率最大的地區

在預測期內，由於肌肉骨骼疾病的高盛行率、高齡化和完善的醫療基礎設施，預計北美將主導肌肉骨骼疾病藥物市場。此外，不斷提高的意識、先進的診斷能力和積極的研究和開發也促進了市場的成長。此外，大型製藥公司的存在和優惠的報銷政策進一步鞏固了北美的地位。

複合年成長率最高的地區：

在預測期內，由於人口高齡化加劇、生活方式改變以及肌肉骨骼疾病盛行率上升，預計亞太地區肌肉骨骼疾病藥物市場將顯著成長。此外，醫療基礎設施的改善、意識的提高和可支配收入的增加也有助於增加獲得先進藥物的機會。此外，製藥公司可能會擴大在該地區的業務，推動肌肉骨骼疾病治療市場的顯著成長。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球肌肉骨骼疾病治療藥物市場：依藥物類型

  • 介紹
  • 止痛藥
  • 皮質類固醇
  • 緩解疾病抗風濕藥物 (DMARD)
  • 其他類型的藥物

第6章全球肌肉骨骼疾病治療市場：依疾病類型

  • 介紹
  • 纖維肌痛
  • 幼年特發性關節炎
  • 骨關節炎
  • 乾癬性關節炎
  • 類風濕性關節炎
  • 脊椎關節炎
  • 其他類型的疾病

第7章全球肌肉骨骼疾病治療市場：依治療類型

  • 介紹
  • 藥品
  • 外科手術
  • 治療
  • 其他治療類型

第8章肌肉骨骼疾病治療藥物的全球市場：依給藥途徑

  • 介紹
  • 口服
  • 胃腸外的
  • 其他給藥途徑

第9章全球肌肉骨骼疾病治療藥物市場：按配銷通路

  • 介紹
  • 醫院藥房
  • 線上提供者
  • 零售藥局和藥局
  • 其他配銷通路

第10章全球肌肉骨骼疾病治療市場：依最終使用者分類

  • 介紹
  • 診斷中心
  • 醫院
  • 風濕病學家
  • 專科診所
  • 其他最終用戶

第11章全球肌肉骨骼疾病治療藥物市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Amgen Inc.
  • AbbVie Inc.
  • Roche Holding AG
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Sanofi
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals, Inc.
  • Biogen Inc.
  • AstraZeneca plc
  • Bristol Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
Product Code: SMRC24420

According to Stratistics MRC, the Global Musculoskeletal Disorders Drugs Market is accounted for $88.6 billion in 2023 and is expected to reach $135.1 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Musculoskeletal disorder drugs are pharmaceuticals designed to treat conditions affecting the muscles, bones, joints, ligaments, and tendons. These disorders encompass a range of conditions, such as arthritis, osteoporosis, and musculoskeletal pain. The drugs aim to alleviate symptoms, manage inflammation, and modify disease progression, contributing to improved mobility and overall musculoskeletal health for individuals affected by these disorders.

According to WHO, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as rheumatoid arthritis, osteoarthritis, low back pain, neck discomfort, fractures, and other injuries.

Market Dynamics:

Driver:

Rising prevalence of musculoskeletal disorders

The escalating prevalence of musculoskeletal disorders acts as a key driver in the musculoskeletal disorders drugs market. Factors such as aging populations, sedentary lifestyles, and an increase in chronic conditions contribute to a growing incidence of musculoskeletal issues like arthritis, osteoporosis, and musculoskeletal pain. This rising prevalence necessitates a corresponding surge in demand for effective pharmaceutical interventions. Consequently, pharmaceutical companies are prompted to invest in research and development, leading to the discovery and production of innovative drugs, thereby propelling the growth of the market.

Restraint:

Adverse side effects and high development costs

The occurrence of adverse effects associated with certain drugs can hinder patient compliance and acceptance. Additionally, the extensive research, development, and clinical trial processes contribute to elevated development costs. The financial burden of these costs may impede pharmaceutical companies from bringing novel and potentially groundbreaking musculoskeletal drugs to market promptly, limiting treatment options for patients impacting the overall growth and accessibility of effective therapies in the market.

Opportunity:

Surging demand for amyotrophic lateral sclerosis drugs

The increasing demand for amyotrophic lateral sclerosis drugs presents a notable opportunity in the musculoskeletal disorders drugs market. As awareness grows, there is a rising need for effective treatments to address this debilitating neurodegenerative disease. Pharmaceutical companies investing in amyotrophic lateral sclerosis drug development can tap into this expanding market, meeting the unmet medical needs of patients. Additionally, this contributes to the overall growth of the market.

Threat:

Insufficient availability of healthcare professionals

Musculoskeletal disorders often require specialized care, diagnosis, and treatment from healthcare professionals such as rheumatologists, orthopedic specialists, and physical therapists. The shortage of these professionals can result in delayed or inadequate patient care, hindering the proper identification and management of musculoskeletal disorders. This scarcity may lead to increased patient wait times, limited access to expert opinions, and challenges in implementing comprehensive treatment plans, affecting overall market growth.

COVID-19 Impact:

The COVID-19 pandemic has impacted the musculoskeletal disorder drug market in various ways. Lockdowns, disruptions in healthcare services, and economic uncertainties have influenced patient access to treatments. Delayed elective procedures and routine care appointments have affected drug consumption patterns. However, increased awareness of musculoskeletal health and the development of innovative telehealth solutions have partially mitigated these challenges during this period.

The juvenile idiopathic arthritis segment is expected to be the largest during the forecast period

The juvenile idiopathic arthritis segment is poised to dominate the musculoskeletal disorders drugs market during the forecast period due to the increasing incidence of juvenile idiopathic arthritis cases. Rising awareness, early diagnosis, and evolving treatment options contribute to the segment's growth. Pharmaceutical advancements, coupled with a focus on pediatric healthcare, drive research and development activities. Additionally, favorable regulatory support and initiatives for rare diseases further propel the prominence of the segment in the market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital segment is primed for substantial growth in the musculoskeletal disorders drug market. Hospitals serve as key healthcare centers for musculoskeletal disorder diagnosis, treatment, and management. The increasing prevalence of these disorders, coupled with a rising aging population, drives the demand for specialized medical care. Additionally, combined with the expanding healthcare infrastructure, the hospital segment is poised for significant growth.

Region with largest share:

Over the forecast period, North America is expected to dominate the Musculoskeletal Disorders Drugs market due to the high prevalence of musculoskeletal disorders, an aging population, and a well-established healthcare infrastructure. Additionally, increasing awareness, advanced diagnostic capabilities, and robust research and development activities contribute to the market's growth. Moreover, the presence of major pharmaceutical companies and favorable reimbursement policies further solidify North America's position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is poised for substantial growth in the Musculoskeletal Disorders Drugs market due to increasing aging populations, lifestyle changes, and a rising prevalence of musculoskeletal disorders. Additionally, improving healthcare infrastructure, growing awareness, and rising disposable incomes contribute to increased accessibility to advanced medications. Moreover, pharmaceutical companies are likely to expand their presence in the region, fostering significant growth in the musculoskeletal disorders drugs market.

Key players in the market:

Some of the key players in Musculoskeletal Disorders Drugs Market include Pfizer Inc., Novartis AG, Johnson & Johnson, Amgen Inc., AbbVie Inc., Roche Holding AG, Merck & Co., Inc., Eli Lilly and Company, Sanofi, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Biogen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd. and Gilead Sciences, Inc.

Key Developments:

In Jun 2022, Pfizer came into collaboration with Sirana Pharma, a Germany-based developer of a biotechnology company. The collaboration involves investigating treatment for a rare bone disease, through leveraging Sirana's microRNA targeting approach.

In March 2022, Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer's Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.

Drug Types Covered:

  • Analgesics
  • Corticosteroids
  • Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Other Drug Types

Disorder Types Covered:

  • Fibromyalgia
  • Juvenile Idiopathic Arthritis
  • Osteoarthritis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Spondylarthritis
  • Other Disorder Types

Treatment Types Covered:

  • Medication
  • Surgery
  • Therapy
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Route of Administrations

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Providers
  • Retail Pharmacy and Drug Stores
  • Other Distribution Channels

End Users Covered:

  • Diagnostic Centers
  • Hospitals
  • Rheumatologists
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Musculoskeletal Disorders Drugs Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Analgesics
  • 5.3 Corticosteroids
  • 5.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
  • 5.5 Other Drug Types

6 Global Musculoskeletal Disorders Drugs Market, By Disorder Type

  • 6.1 Introduction
  • 6.2 Fibromyalgia
  • 6.3 Juvenile Idiopathic Arthritis
  • 6.4 Osteoarthritis
  • 6.5 Psoriatic Arthritis
  • 6.6 Rheumatoid Arthritis
  • 6.7 Spondylarthritis
  • 6.8 Other Disorder Types

7 Global Musculoskeletal Disorders Drugs Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Medication
  • 7.3 Surgery
  • 7.4 Therapy
  • 7.5 Other Treatment Types

8 Global Musculoskeletal Disorders Drugs Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parenteral
  • 8.4 Other Route of Administrations

9 Global Musculoskeletal Disorders Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Providers
  • 9.4 Retail Pharmacy and Drug Stores
  • 9.5 Other Distribution Channels

10 Global Musculoskeletal Disorders Drugs Market, By End User

  • 10.1 Introduction
  • 10.2 Diagnostic Centers
  • 10.3 Hospitals
  • 10.4 Rheumatologists
  • 10.5 Specialty Clinics
  • 10.6 Other End Users

11 Global Musculoskeletal Disorders Drugs Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Novartis AG
  • 13.3 Johnson & Johnson
  • 13.4 Amgen Inc.
  • 13.5 AbbVie Inc.
  • 13.6 Roche Holding AG
  • 13.7 Merck & Co., Inc.
  • 13.8 Eli Lilly and Company
  • 13.9 Sanofi
  • 13.10 GlaxoSmithKline plc
  • 13.11 Regeneron Pharmaceuticals, Inc.
  • 13.12 Biogen Inc.
  • 13.13 AstraZeneca plc
  • 13.14 Bristol Myers Squibb Company
  • 13.15 Takeda Pharmaceutical Company Limited
  • 13.16 F. Hoffmann-La Roche Ltd.
  • 13.17 Gilead Sciences, Inc.

List of Tables

  • Table 1 Global Musculoskeletal Disorders Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Musculoskeletal Disorders Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Musculoskeletal Disorders Drugs Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 4 Global Musculoskeletal Disorders Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Musculoskeletal Disorders Drugs Market Outlook, By Disease-Modifying Antirheumatic Drugs (DMARDs) (2021-2030) ($MN)
  • Table 6 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 7 Global Musculoskeletal Disorders Drugs Market Outlook, By Disorder Type (2021-2030) ($MN)
  • Table 8 Global Musculoskeletal Disorders Drugs Market Outlook, By Fibromyalgia (2021-2030) ($MN)
  • Table 9 Global Musculoskeletal Disorders Drugs Market Outlook, By Juvenile Idiopathic Arthritis (2021-2030) ($MN)
  • Table 10 Global Musculoskeletal Disorders Drugs Market Outlook, By Osteoarthritis (2021-2030) ($MN)
  • Table 11 Global Musculoskeletal Disorders Drugs Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 12 Global Musculoskeletal Disorders Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 13 Global Musculoskeletal Disorders Drugs Market Outlook, By Spondylarthritis (2021-2030) ($MN)
  • Table 14 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Disorder Types (2021-2030) ($MN)
  • Table 15 Global Musculoskeletal Disorders Drugs Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 16 Global Musculoskeletal Disorders Drugs Market Outlook, By Medication (2021-2030) ($MN)
  • Table 17 Global Musculoskeletal Disorders Drugs Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 18 Global Musculoskeletal Disorders Drugs Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 19 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 20 Global Musculoskeletal Disorders Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 21 Global Musculoskeletal Disorders Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 22 Global Musculoskeletal Disorders Drugs Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 23 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 24 Global Musculoskeletal Disorders Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 25 Global Musculoskeletal Disorders Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 26 Global Musculoskeletal Disorders Drugs Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 27 Global Musculoskeletal Disorders Drugs Market Outlook, By Retail Pharmacy and Drug Stores (2021-2030) ($MN)
  • Table 28 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 29 Global Musculoskeletal Disorders Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Musculoskeletal Disorders Drugs Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 31 Global Musculoskeletal Disorders Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 32 Global Musculoskeletal Disorders Drugs Market Outlook, By Rheumatologists (2021-2030) ($MN)
  • Table 33 Global Musculoskeletal Disorders Drugs Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 34 Global Musculoskeletal Disorders Drugs Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.